New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 randomized controlled trial published in The Lancet. Additionally, participants taking orforglipron had significantly greater reductions in body weight than those taking oral semaglutide.